The study, published in Nature Aging, found that FTL1 builds up in the hippocampus, the brain’s memory center, as mice get older. Too much of this protein disrupts brain function. Older mice with elevated FTL1 performed poorly on memory tasks. To confirm the link, scientists boosted FTL1 in younger mice.

To confirm the link, scientists boosted FTL1 in younger mice. These healthy mice quickly developed memory problems similar to older ones. But when scientists lowered FTL1 levels in aging mice, something remarkable happened: their memory improved to the level of much younger mice.

How FTL1 Affects the Brain

FTL1 helps store iron inside cells, but when it builds up in the brain, it disrupts how neurons generate and use energy. Neurons need energy to build and maintain connections, which are the pathways for learning and memory.

When FTL1 levels rise, neurons lose power. They cannot store information as effectively, leading to forgetfulness. Scientists also observed that older mice with high FTL1 had fewer connections between brain cells.

The team used advanced tools, including viruses and genetic methods, to change FTL1 levels. They then put mice through memory and learning challenges, such as solving mazes and recognizing objects. After reducing FTL1, older mice performed almost as well as young mice, proving that brain function could be restored.

The research also tested metabolism. Researchers discovered that when FTL1 levels rise, neurons struggle to produce enough energy. When they added NADH, a compound that helps with cell energy, memory problems improved. This suggests that targeting brain energy systems could be another way to help with memory loss reversal.

What This Means for Humans

While the results are exciting, the research is still at an early stage. The experiments were done only in male mice, and the human brain is far more complex. A treatment that works in mice may not work the same way in people.

Currently, there are no safe drugs that directly reduce FTL1 in humans. The methods used in the study involved genetic tools, not medicines. Researchers warn that it could take years before this discovery leads to new therapies.

Still, the findings are important because they focus on normal, age-related memory decline, not just diseases like Alzheimer’s. Almost everyone experiences some memory loss with age. By targeting FTL1, scientists may one day find a way to help a much larger group of people.

In the United States, between six and 12 million people over 65 live with mild cognitive impairment, a condition that often leads to dementia. About one-third of them develop Alzheimer’s within five years. For these individuals, new options for memory loss reversal could make a huge difference.

A New Direction in Brain Research

For decades, dementia research has centered on proteins like beta-amyloid and tau, which form clumps and tangles in the brain. The UCSF study adds a new angle by showing that iron-related proteins and energy systems may also be key to memory decline.

By focusing on FTL1, scientists are opening doors to treatments that could help almost everyone as they grow older—not just those with Alzheimer’s disease.

[Source]

The post Scientists Find Way to Reverse Memory Loss in Mice appeared first on Medical Journal Daily.

This research not only offers a new therapeutic avenue but also sheds light on the shared biological mechanisms that may link autism and epilepsy.

The Study

The study focused on the reticular thalamic nucleus (RT), a part of the brain responsible for processing sensory information. The researchers used mouse models of autism spectrum disorder (ASD), which were genetically modified with mutations in the CNTNAP2 gene, a gene strongly associated with autism.

These mice exhibited classic autism-like behaviors, including repetitive grooming, social withdrawal, hyperactivity, and an increased susceptibility to seizures. The scientists discovered that the neurons in their RT were overactive, a phenomenon linked to strong currents in what are known as T-type calcium channels.

The team then introduced Z944, also known as ulixacaltamide, a drug being studied as a potential treatment for seizure disorders. Z944 is a T-type calcium channel antagonist, meaning it works by blocking these specific currents.

The results were nothing short of remarkable. After administering just one dose of Z944, the mice showed a significant reversal of their autistic behaviors. Their repetitive grooming decreased, they became more socially interactive, and their hyperactivity was reduced.

The drug appeared to “quiet” the overactive RT region, leading to a profound change in their behavior. This finding was further validated when the researchers genetically modified the mice to have increased activity in the RT, causing the autistic behaviors to return.

This suggests that Z944’s ability to suppress this specific brain region is the key to its therapeutic effect.

The Overlap Between Autism and Epilepsy

The findings of this study provide crucial evidence for a long-suspected connection between autism and epilepsy. Autistic individuals are up to 30 times more likely to develop epilepsy than the general population. This high comorbidity has led experts to believe that the two conditions may share underlying biological mechanisms, and this new research strongly supports that theory.

The study suggests that the same overactive neural circuits and channels in the RT that contribute to autistic symptoms may also be a factor in seizure activity. This potential overlap not only explains why the conditions often coexist but also highlights a promising new target for treatment that could address both simultaneously.

While the prospect of a single-dose treatment is exciting, the researchers are quick to emphasize that these findings are still preliminary and based on animal models.

It remains unclear how these results will translate to humans. However, the study provides a critical framework for future research. The scientists note that the next steps should focus on understanding how the RT’s influence on the broader brain circuitry affects the full spectrum of ASD behaviors.

This knowledge could pave the way for highly precise, circuit-specific interventions tailored to the needs of individuals with autism. As Z944 continues its clinical trials for epilepsy, its potential as a dual-purpose drug for both epilepsy and autism remains a captivating possibility that could fundamentally change the lives of millions.

[Source]

The post New Seizure Drug Shows Promise in Reversing Autism Symptoms in Mice appeared first on Medical Journal Daily.

The illness is defined by an overwhelming and unrelenting fatigue that does not improve with rest, often coupled with pain, cognitive difficulties, and post-exertional malaise—a sudden worsening of symptoms after even small amounts of physical or mental activity. Despite its impact, there has been no diagnostic test, no clear biological explanation, and no proven cure.

Now, a major genetic study is beginning to change that narrative. The DecodeME project, launched in 2022 and led by scientists at the University of Edinburgh with support from patient advocacy groups, has provided the strongest evidence yet that biology—rather than behavior or psychology—plays a central role in ME/CFS.

Eight Genetic Signals—What They Reveal

Researchers examined DNA samples from more than 15,000 people with the illness and compared them to over 250,000 individuals without it. What they found was striking: eight regions of DNA where genetic differences were far more common among patients than in the general population.

These differences, often referred to as “genetic signals,” appear to cluster around two key biological systems—the immune system and the nervous system. Some of the genes identified are known to influence how the body responds to infection, a finding that echoes the experiences of many patients who report that their illness began after a viral or bacterial illness.

Others are linked to pathways involved in pain regulation, which may help explain why chronic pain is such a common feature of the condition.

Importantly, the study also showed that these genetic differences are not associated with psychiatric conditions such as depression or anxiety, helping to counter the long-standing misconception that ME/CFS is primarily psychological in nature.

Implications

The implications of these findings are significant, though researchers caution that they are only the beginning. The genetic associations discovered by DecodeME cannot yet be used to diagnose the illness, nor do they immediately translate into treatment.

What they do provide, however, is a roadmap for future research—clues that point scientists toward the biological processes most likely driving ME/CFS. By focusing on immune and neurological pathways, researchers may be able to develop targeted studies and, eventually, new therapies that address the underlying mechanisms rather than just the symptoms.

For patients, the study represents more than just scientific progress—it is also a moment of validation. ME/CFS has historically been misunderstood, with many sufferers facing disbelief from clinicians, employers, and even friends or family. The discovery that the illness is written, at least in part, into the genome underscores that it is not imagined, but rooted in biology. As Professor Chris Ponting, who leads the DecodeME study, has noted, these results mark a turning point in how the illness is perceived within the medical and research communities.

Future Directions

The DecodeME team is continuing its work, expanding the study to include participants from more diverse backgrounds and conducting deeper analyses of genetic variation. They have also made their dataset available to scientists around the world in the hope that collaboration will accelerate discoveries.

While it may take years to translate these findings into practical treatments, the momentum is now firmly on the side of progress. For a patient community that has long waited for recognition and solutions, this study offers both a clearer biological foundation and a renewed sense of hope.

[Source]

The post Major Study Reveals Genetic Roots of Chronic Fatigue Syndrome appeared first on Medical Journal Daily.

Rewriting Gene Activity in the Diseased Brain

Alzheimer’s disease disrupts how genes operate in brain cells. To understand this better, scientists first mapped the patterns of gene activity in individual neurons and support cells (called glia) from brains affected by the disease. This process, known as gene expression profiling, shows which genes are active or dormant. The researchers then searched for drugs that could flip those patterns back toward normal.

They turned to a large public database called the Connectivity Map, which catalogs how thousands of drugs affect gene activity in human cells. Out of 1,300 drugs, just 10 reversed Alzheimer’s-linked gene patterns across different brain cell types, and only five were already approved by the U.S. Food and Drug Administration.

Using medical records from over 1.4 million patients across California’s university hospitals, the researchers looked for any real-world signs that those drugs might help prevent Alzheimer’s. The records showed that people who had taken some of these medications, mostly for cancer, appeared less likely to develop the disease later on.

Targeting Two Cell Types with a Two-Drug Combo

From this shortlist, the team selected two drugs: letrozole, typically used to treat breast cancer, and irinotecan, used against colon and lung cancers. They believed each drug would target a different cell type — letrozole for neurons and irinotecan for glia — like a two-part key unlocking different doors in the brain.

When given to mice with advanced Alzheimer’s-like symptoms, the drug duo had striking effects. It stopped further damage, reduced toxic protein buildup, and even restored the animals’ ability to remember how to navigate mazes. Memory, in this case, was not just protected, it was brought back from the edge.

The researchers compare the process to rewiring a city after a blackout, where different crews work on separate grid sections, but the lights only come back when efforts are synchronized. Similarly, targeting both neurons and glia may be the missing link that single-drug strategies have overlooked.

A Possible Turning Point for Alzheimer’s Treatment

“This study opens a new door using drugs we already have,” said lead researcher Yadong Huang. His team emphasizes that although results in mice are promising, human trials are essential to confirm safety and effectiveness.

Letrozole and irinotecan, though widely used in cancer treatment, can come with serious side effects. If repurposed for Alzheimer’s, their doses and delivery methods will likely need major adjustments. The upside? Since the drugs are already approved, clinical trials could begin sooner than if researchers had to start from scratch.

With over 55 million people living with Alzheimer’s worldwide and that number set to double in the next two decades.

As co-author Marina Sirota puts it, “When two completely different kinds of data — from cells and from real patients — lead to the same drug, and it works in a model of the disease, we may finally be onto something.”

[Source]

The post Two Cancer Drugs Show Surprising Potential Against Alzheimer’s in Early Tests appeared first on Medical Journal Daily.

This failure in cellular housekeeping, researchers say, could be more than a side effect. It might be a core issue in the development of autism and possibly other brain-related disorders such as schizophrenia.

The Search for a Consistent Model

Autism spectrum disorder is known to be influenced by genetics, but the range of mutations linked to the condition has made it difficult to study. Each variation may affect a different biological pathway, making it challenging to find patterns.

In an effort to make sense of autism’s genetic complexity, neuroscientist Takumi Toru and his team dedicated over ten years to developing a uniform research system.

They turned to mouse embryonic stem cells—versatile cells capable of transforming into virtually any cell type—to build a foundation for studying autism-linked mutations in a controlled and repeatable way.

By combining this flexibility with CRISPR gene editing, the team created 63 lines of stem cells—each carrying one of the autism-linked genetic changes found in human studies.

These stem cells can be turned into neurons or even grown into mice, allowing researchers to study how each mutation plays out in brain development and behavior.

A Closer Look at Neuronal Behavior

To test the new models, the researchers grew neurons from 12 of the 63 cell lines and studied their genetic activity in detail. One pattern stood out. A number of the neurons had unusually low levels of a gene called Upf3b, which helps identify and eliminate misshapen or excess proteins.

Protein production in neurons is a high-stakes process. These cells make proteins locally in their extensions and connections, not just in the cell body. This allows them to respond quickly, but it also means that any quality control failure could cause local dysfunction.

“When we looked at the data, it was clear that something was wrong with the way these neurons were managing their proteins,” said a researcher from the Kobe team. “The same types of problems appeared again and again across different genetic models.”

Shared Features Across Brain Disorders

The finding may not be limited to autism. Many of the genetic mutations studied in the Kobe models are also associated with conditions like bipolar disorder and schizophrenia. These disorders share some symptoms with autism, such as difficulties with communication or sensory processing, though they differ in onset and severity.

If a common failure in protein regulation is involved in all three, it could point to a broader mechanism that affects how the brain develops and maintains its functions.

This idea is supported by previous findings from other research teams, which have noticed similar problems in protein handling in postmortem brain tissue from people with psychiatric disorders. But until now, there has not been a controlled way to study these issues across multiple mutations in a single system.

From Cell Lines to Practical Research

The 63 mouse stem cell lines developed by the Kobe team are now available for other researchers to use. This means scientists working in drug development or brain imaging can begin testing whether interventions that improve protein quality control also reduce traits associated with autism.

In one experiment at Kobe, researchers grew full adult mice from the engineered cells. Some showed repetitive behavior patterns, such as touching their whiskers to the same spot in their enclosure over and over again. Follow-up analysis of their neurons showed a buildup of malformed proteins, suggesting a possible connection between this microscopic dysfunction and outward behavior.

The hope is that focusing on these shared cellular weaknesses may help simplify autism research by highlighting common vulnerabilities, rather than trying to track the effects of every individual mutation.

Takumi and his team are careful to note that this approach does not explain all aspects of autism, which remains a complex and highly variable condition. But identifying a failure in protein cleanup as a repeatable feature is a step toward understanding what makes the condition appear across different people with different genetic backgrounds.

Looking Ahead

This work marks a shift in autism research from tracking genes individually to understanding the cellular systems they affect. If future studies confirm that protein regulation is a weak point in early brain development, then therapies could be designed to target this process—potentially offering a new approach for early intervention.

For now, the Kobe stem cell bank stands as a shared platform for scientists worldwide to explore the biology of autism and related disorders using a consistent and flexible set of tools.

[Source]

The post Mouse Stem Cell Models Reveal a Surprising Link Between Faulty Protein Control and Autism Traits appeared first on Medical Journal Daily.

The findings don’t just confirm what we’ve suspected — they also point to sleep quality as a potentially modifiable risk factor for Alzheimer’s. That means better sleep habits could play a role in protecting long-term brain health.

The Brain-Sleep Connection: What the Study Found

In a cohort of 270 participants tracked over 13 to 17 years as part of the Atherosclerosis Risk in Communities Study, researchers analyzed sleep patterns recorded through polysomnography and compared them to brain MRIs taken more than a decade later. They focused on specific regions vulnerable to Alzheimer’s, including the hippocampus, inferior parietal lobule, precuneus, and cuneus.

Participants who spent less time in SWS and REM sleep showed significantly smaller volumes in key brain areas. For example, every 1% drop in SWS was linked to a 44.18 mm³ smaller volume in the inferior parietal lobule.

Similarly, less REM sleep was associated with smaller volumes in both the inferior parietal region and precuneus. These changes align closely with early signs of neurodegeneration seen in Alzheimer’s.

Importantly, the arousal index — a measure of how often someone wakes up during sleep — did not show a meaningful association with brain atrophy. Nor did any of the sleep variables predict the presence of cerebral microbleeds, which are also linked to aging and dementia but were not the focus here.

Why Deep and REM Sleep Matter

Deep sleep isn’t just downtime. During slow-wave sleep, the brain carries out critical cleanup tasks — clearing out waste products, including potentially harmful proteins like beta-amyloid, which is strongly associated with Alzheimer’s.

REM sleep, on the other hand, supports memory consolidation and emotional processing. It’s also when the brain integrates sensory information and reinforces learning.

So it’s not surprising that brain regions responsible for complex functions like visuospatial awareness — such as the inferior parietal lobule — are especially affected by reductions in deep and REM sleep. This region synthesizes sensory input and plays a role in how we understand our environment, which often becomes impaired early in Alzheimer’s progression.

Can You Improve Deep Sleep?

The good news is that improving deep sleep isn’t as difficult as it might seem. Experts note that both deep and REM sleep depend more on consistent, high-quality rest than just spending extra hours in bed. In fact, routines and environment play a bigger role than duration alone.

Maintaining healthy sleep habits—like sticking to a regular bedtime, keeping the bedroom dark and quiet, and steering clear of screens, caffeine, or alcohol in the evening—can significantly impact how restorative your sleep is. Even small calming rituals, such as a warm shower or gentle stretching before bed, may support deeper sleep.

Still, it’s worth noting that as we age, getting the same amount of deep sleep becomes more challenging, making those healthy habits even more important.

Evidence shows that even small improvements in sleep quality can benefit cognitive function. A separate 2023 study even linked strong sleep habits with longer life expectancy — nearly five years for men and 2.5 years for women.

As Dr. Richard Issacson, a preventive neurologist, pointed out, clinical experience backs these findings. In his work with at-risk adults, deeper sleep has consistently predicted better brain volume and cognitive outcomes.

Bottom Line: The link between deep sleep and Alzheimer’s is real and measurable. While genetics and other risk factors remain important, sleep is one area we can actively work on. Making sleep a priority isn’t just about feeling rested — it could help protect your brain in the long run.

[Source]

The post Lack of Deep Sleep Increases Alzheimer’s Risk appeared first on Medical Journal Daily.

When the episode aired in 2013, he sought the expertise of a medical professional, who confirmed his condition, stating that his genitals were underdeveloped.

Years later, Brandon participated in an AMA(Reddit), where he elaborated on his life experiences and the treatments he pursued following the show.

Reflecting on his youth, he said, “I always knew something was off with my body but didn’t seriously address it until my late teens. I needed a physical to join my high school soccer team, and that’s when I asked the doctor why I hadn’t gone through puberty. He brushed it off, saying I was just a late bloomer.”

Brandon admitted that he didn’t think much of it at the time, choosing to focus on school and work. After finishing school, he experienced a significant growth spurt, shooting up from 5’4” to 6’3”. While it seemed like he was finally developing, he later realized he should have sought medical advice earlier.

Following personal struggles, including a divorce and unemployment, Brandon decided to research his symptoms. After months of self-study, he diagnosed himself with Kallmann syndrome, a genetic condition characterized by the delayed or absent onset of puberty.

For the past two years, Brandon has undergone testosterone replacement therapy (TRT) three times, each lasting 2-3 months. However, the costs of frequent doctor visits, blood work, and medication have been overwhelming. Despite applying for medical assistance, he was denied, as his condition wasn’t deemed severe enough.

Before his appearance on The Doctors, Brandon had no body hair, minimal pubic and armpit hair, and no facial hair. His testes, he said, were the size of marbles and would only grow with specialized hormone therapy.

Though people often perceive him as younger than he is, Brandon said he has come to terms with this. “Once I explain my condition, they usually understand and treat me appropriately,” he noted.

2023 Update

Brandon has shared that most of his health issues are “invisible illnesses,” which are hard to detect unless someone witnesses him experiencing a migraine or muscle cramps. For 37 years, he has lived in a state of constant exhaustion.

Over the past 27 days, he has had a constant headache, fluctuating from mild to severe migraines. He attributes this to allergies, which worsened after starting allergy injections about a month ago.

Around two years ago, Brandon was diagnosed with celiac disease. Upon receiving the diagnosis, he immediately purged his home of gluten-containing foods and adopted a new diet. After six months with no improvement, he saw a gastroenterologist and was also diagnosed with microscopic colitis.

Many foods still upset his stomach, which triggers muscle cramps. Brandon maintains a limited diet, eating only 4-5 meals. While his muscle spasms have improved with dietary changes, he has torn five muscles in the past three years, two of which were severe. His primary care doctor finally referred him to a neurologist, who has since referred him to the University of Utah for further testing, focusing on metabolic and serotonin disorders.

Brandon’s muscle spasms vary, ranging from tremors to cramping that can last seconds to hours. They often occur in multiple muscles simultaneously. On a good night, he wakes up with mild cramps 3-5 times, while bad nights see him waking up as many as 20 times. Despite these challenges, Brandon noted that his health has improved over the past two years, though it’s still not where he would like it to be.

The post What Happened to Brandon Westfall? The 27-Year-Old Who Struggled with Puberty appeared first on Medical Journal Daily.